Test Price
2,800 AED✅ Home Collection Available
PYCR1 Gene, Cutis Laxa Type 2B, Autosomal Recessive Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين PYCR1 للكشف عن الجلد المترهل من النوع 2B المتنحي الجسمي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & Quality Assurance
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139) utilizing Next-Generation Sequencing (NGS).
- ✓ Premium Logistics: Paid, Hospital-Grade Home Collection via ISO Certified Cold-Chain and VIP Mobile Phlebotomy service (8 AM - 11 PM).
- ✓ Clinical Guidance: Mandatory pre-test genetic counselling session and telephonic post-test clinical guidance for result interpretation.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
الملخص التنفيذي: فحص جيني متطور من الجيل التالي (NGS) لتحديد الطفرات في جين PYCR1 المرتبط بالجلد المترهل من النوع 2B المتنحي الجسمي. يمثل هذا التحليل أداة تشخيصية دقيقة وفقاً لأعلى معايير هيئة الصحة بدبي (DHA) والقانون الاتحادي رقم 41 لعام 2024، لضمان إدارة سريرية آمنة وفعالة للمرضى.
Clinical Overview & Differential Advantage
This test analyzes the PYCR1 gene to confirm a molecular diagnosis of Autosomal Recessive Cutis Laxa Type 2B (ARCL2B), a severe connective tissue disorder characterized by progeroid features and developmental delay. Our protocol provides the definitive genetic blueprint essential for multidisciplinary management, surpassing the limitations of symptomatic dermatological evaluation.
| Feature | Our Test (AMOL Laboratory) | Closest Alternative |
|---|---|---|
| Precision | NGS with full gene coverage & CNV analysis | Single-gene Sanger sequencing |
| Methodology | LC-MS/MS validated library preparation & bioinformatics pipeline | Standard PCR-based screening |
| Diagnostic Speed | 3 to 4 Weeks with robust clinical report | Often 6-8 weeks or non-diagnostic |
Physician Insight & Holistic Safety Protocol
"As a clinical pathologist, I must emphasize that a diagnosis of PYCR1-related cutis laxa is a lifelong journey requiring coordinated care; this genetic test result is the critical first map, not the final destination. We stand by to guide the interpretation, integrating genomic data with your child's unique clinical presentation. I urge families to view this result as a powerful tool for proactive multi-system surveillance, from osteology to dermatology, rather than a definitive sentence."
— Dr. PRABHAKAR REDDY (DHA License: 61713011)
Medication & Pre-Test Safety Warning
Do not discontinue any prescribed medication or supplement without explicit consultation with your managing physician. The sample type of "Blood or Extracted DNA or One drop Blood on FTA Card" does not exempt you from the mandatory pre-test genetic counselling session.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent or a clinical history/pedigree chart.
- Exclusion: Recent hematopoietic stem cell transplant (may require alternative sample type).
- Exclusion: Active systemic infection unmanaged prior to blood draw (consult physician).
- ER Red Flag: If the patient exhibits acute neurological regression, intractable seizures, or severe respiratory distress, seek emergency care immediately; do not wait for genetic test results.
Patient FAQ & Clinical Navigation
1. What does the PYCR1 gene NGS test definitively diagnose, and why is it crucial for my child's multi-systemic health?
This NGS test definitively identifies mutations in the PYCR1 gene to confirm Autosomal Recessive Cutis Laxa Type 2B, a condition impacting the skin, skeleton, and brain. Because the clinical presentation mimics other progeroid syndromes, a precise genetic diagnosis is the only way to initiate targeted surveillance for life-threatening complications like aortic root dilatation or severe osteopenia, moving care from observation to proactive management.
2. Why is a genetic counselling session and a detailed pedigree chart mandatory before I can give a blood sample?
The mandatory pre- genetic counselling session ensures fully informed consent and constructs a pedigree chart to map the autosomal recessive inheritance pattern, directly guiding the laboratory's data interpretation. This clinical context, required under the UAE CDS Law 2026 for minor protection, is critical for the bioinformatics team to distinguish rare benign family variants from a truly disease-causing mutation, ensuring report accuracy.
٣. ما هي مدة انتظار النتائج وهل الاكتشاف المتأخر للطفرة الجينية أكثر خطورة؟
فترة انتظار النتائج هي 3 إلى 4 أسابيع، وهذه المدة ضرورية لضمان دقة التشخيص الجزيئي عبر تقنية التسلسل المتقدم. التأخر في تحديد الطفرة الجينية لجين PYCR1 يحمل خطورة متزايدة لبدء العلاج الداعم متعدد التخصصات، حيث أن التشخيص المبكر يمكّن من مراقبة المضاعفات الهيكلية والعصبية والتدخل الاستباقي المبكر للحفاظ على جودة الحياة.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians